CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@H]21)S(=O)(=O)c1ccc(N)cc1.CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1CXORHDVSJFELCV-HWDLLDTBSA-NPrezcobix and Prezcobix PED are prescription medicines approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV in adults and children 3 years of age and older who weigh at least 33 lb (15 kg) and meet certain requirements, as determined by a health care provider. Prezcobix and Prezcobix PED are always used in combination with other HIV medicines.
DTXSID601336377J - Antiinfectives for systemic use
QJ - Antiinfectives for systemic use
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A.
現在のフィルター条件では反応記録がありません。
読み込み中…